PALO ALTO, Calif., April 20, 2021-- TCG Crossover (“TCG X”), in partnership with The Column Group, has raised an inaugural $824 million fund focused on crossover and public investments in the life sciences. The oversubscribed fund attracted an array of premier investors including university endowments, family offices, pension funds and sovereign wealth funds. TCG X invests exclusively in innovative drug discovery companies that are seeking to make an impact on unmet medical needs. By leveraging its relationship with The Column Group and its Science Partners, the firm adds extensive scientific and operating expertise to its portfolio companies.